Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  panobinostat
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 64 for your search:
Start Over
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk MDS
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589BDE04, EudraCT 2009-010403-84, 2009-010403-84, NCT01034657
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589DUS71, NCT01083602
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 120
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2201, 2006-000880-27, NCT00425555
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2211, NCT00449761
Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2202, NCT00451035
Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2212, NCT00490776
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589D2308, 2009-015507-52, NCT01023308
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589E2301, 2009-014846-26, NCT01034163
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2102, NCT00621244
LBH589 Plus Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 60 and over
Sponsor: Other
Protocol IDs: 08-0172 / 201012979, NCT00691938
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000612441, ONCOTHER-CLBH589BUS15T, LBH, CLBH589BUS15T, NCT00743288
Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 65 and over
Sponsor: Other
Protocol IDs: PANOBIDARA, NCT00840346
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-342, CLBH589BUS42T, NCT00859222
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 08-479, NCT00878436
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0805, NCI-2011-03023, NCT00967044
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: N093B, NCCTG-N093B, CDR0000669300, NCI-2011-02035, NCT01105312
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-15618, CLBH589BUS20T, NCT01111526
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI MM 27, NCT01496118
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GU 49, NCT00550277
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI MDS 07, NCT00594230
Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589C2208, NCT00667862
Phase II Trial of LBH589 in Refractory Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CLBH589BUS19T, CRC GOLP CNOV 0823, NCT00690677
Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589E2214, 2008-003016-35, NCT00742027
Study of Panobinostat Monotherapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: TRIO 017, NCT00777049
Efficacy and Safety of Panobinostat (LBH5789) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2213, 2008-002983-32, NCT00880269
Start Over